Despite steep costs, payments for new cancer drugs make economic sense

Nature Medicine

Volumn 17, Issue 3, 2011, Pages 244-

  Lichtenberg, Frank R ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

DRUG COST; ECONOMICS; HUMAN; NEOPLASM; NOTE;

ANTINEOPLASTIC AGENTS; DRUG COSTS; HUMANS; NEOPLASMS;

EID: 79955857876     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0311-244     Document Type: Article

References (7)

1. Kantarjian, H. et al. Cancer 103, 2099–2108 (2005).
2. Richardson, P.G. et al. N. Engl. J. Med. 352, 2487–2498 (2005).
3. von der Maase, H. et al. J. Clin. Oncol. 23, 4602–4608 (2005).
4. Johnson, J., Williams, G. & Pazdur, R. J. Clin. Oncol. 21, 1404–1411 (2003).
5. Lichtenberg, F.R. Econom. Innov. New Technol. 18, 407–428 (2009).
6. Lichtenberg, F.R. NBER Work. Pap. Ser. 15880 (2010).
7. Braithwaite, R.S., Meltzer, D.O., King, J.T. Jr., Leslie, D., Roberts, M.S. Med. Care 46, 349–356 (2008).